Provided by Tiger Fintech (Singapore) Pte. Ltd.

Citius Pharmaceuticals, Inc.

1.08
+0.167418.34%
Post-market: 1.130.0500+4.63%19:59 EDT
Volume:2.91M
Turnover:3.19M
Market Cap:12.07M
PE:-0.19
High:1.24
Open:0.9380
Low:0.8822
Close:0.9126
Loading ...

Citius Oncology On Track to Launch Lymphir in US in H2

MT Newswires Live
·
17 Jun

Citius Oncology expects commercial launch of Lymphir in second half of 2025

TIPRANKS
·
17 Jun

Citius Oncology Inc - Anticipates Commercial Launch of Lymphir in 2025

THOMSON REUTERS
·
17 Jun

Citius Pharmaceuticals Inc. Announces $15.8 Million Registered Direct Offering to Support LYMPHIR™ Launch

Reuters
·
12 Jun

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of up to $15.8 Million Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
12 Jun

Citius Pharmaceuticals price target lowered to $6 from $9 at D. Boral Capital

TIPRANKS
·
11 Jun

Top Midday Decliners

MT Newswires Live
·
11 Jun

Citius Pharmaceuticals announces $15.8M registered direct offering

TIPRANKS
·
10 Jun

Citius Pharmaceuticals Announces a Registered Direct Offering of up to $15.8 Million Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
10 Jun

Citius Pharmaceuticals Inc. Held Special Meeting to Amend Articles of Incorporation

Reuters
·
10 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Chip Stocks, EchoStar

Reuters
·
10 Jun

Citius Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
09 Jun

BRIEF-Citius Oncology Enters Into Distribution Services Agreement With Cardinal Health

Reuters
·
09 Jun

Citius Oncology Signs US Distribution Deal With Cardinal Health for Lymphir

MT Newswires Live
·
09 Jun

Citius Oncology Inc - Agreement Supports Upcoming Launch of Lymphir for Ctcl Treatment

THOMSON REUTERS
·
09 Jun

Citius Oncology Enters Into Distribution Services Agreement With Cardinal Health

THOMSON REUTERS
·
09 Jun

Citius Pharmaceuticals Inc. Issues $1 Million Promissory Note with 15% Interest Rate, Due December 2025

Reuters
·
04 Jun

Citius Pharmaceuticals Inc - Not in Compliance With Nasdaq Minimum Bid Price - SEC Filing

THOMSON REUTERS
·
31 May

Citius Pharmaceuticals Faces Nasdaq Delisting Due to Non-Compliance with Minimum Bid Price Rule

Reuters
·
31 May

Citius Pharmaceuticals Cut to Hold From Buy by Maxim Group

Dow Jones
·
23 May